MIT-IBM Watson AI Lab, Cambridge, MA, USA; IBM Research, Yorktown Heights, NY, USA.
MIT-IBM Watson AI Lab, Cambridge, MA, USA; Massachusetts Institute of Technology, Cambridge, MA, USA.
Br J Anaesth. 2021 Oct;127(4):569-576. doi: 10.1016/j.bja.2021.04.035. Epub 2021 Jul 10.
Fluid overload is associated with poor outcomes. Clinicians might be reluctant to initiate diuretic therapy for patients with recent vasopressor use. We estimated the effect on 30-day mortality of withholding or delaying diuretics after vasopressor use in patients with probable fluid overload.
This was a retrospective cohort study of adults admitted to ICUs of an academic medical centre between 2008 and 2012. Using a database of time-stamped patient records, we followed individuals from the time they first required vasopressor support and had >5 L cumulative positive fluid balance (plus additional inclusion/exclusion criteria). We compared mortality under usual care (the mix of care actually delivered in the cohort) and treatment strategies restricting diuretic initiation during and for various durations after vasopressor use. We adjusted for baseline and time-varying confounding via inverse probability weighting.
The study included 1501 patients, and the observed 30-day mortality rate was 11%. After adjusting for observed confounders, withholding diuretics for at least 24 h after stopping most recent vasopressor use was estimated to increase 30-day mortality rate by 2.2% (95% confidence interval [CI], 0.9-3.6%) compared with usual care. Data were consistent with moderate harm or slight benefit from withholding diuretic initiation only during concomitant vasopressor use; the estimated mortality rate increased by 0.5% (95% CI, -0.2% to 1.1%).
Withholding diuretic initiation after vasopressor use in patients with high cumulative positive balance (>5 L) was estimated to increase 30-day mortality. These findings are hypothesis generating and should be tested in a clinical trial.
液体超负荷与不良结局相关。对于近期使用血管加压药物的患者,临床医生可能不愿意开始使用利尿剂治疗。我们评估了在可能存在液体超负荷的患者中,在使用血管加压药物后停止或延迟使用利尿剂对 30 天死亡率的影响。
这是一项回顾性队列研究,纳入了 2008 年至 2012 年期间在学术医疗中心 ICU 住院的成年人。使用带时间戳的患者记录数据库,我们从患者首次需要血管加压药物支持并累积正液体平衡>5 L(加上其他纳入/排除标准)时开始对个体进行随访。我们比较了常规治疗(队列中实际提供的治疗组合)和在使用血管加压药物期间和之后的不同时间段限制利尿剂起始的治疗策略下的死亡率。我们通过逆概率加权法调整了基线和随时间变化的混杂因素。
这项研究纳入了 1501 名患者,观察到的 30 天死亡率为 11%。在调整了观察到的混杂因素后,与常规治疗相比,在停止最近一次血管加压药物使用后至少 24 小时停止使用利尿剂,估计会使 30 天死亡率增加 2.2%(95%置信区间,0.9%-3.6%)。数据与仅在同时使用血管加压药物时延迟利尿剂起始的中度危害或轻微获益一致;估计死亡率增加了 0.5%(95%置信区间,-0.2%至 1.1%)。
在累积正平衡(>5 L)较高的患者中,在使用血管加压药物后停止使用利尿剂,估计会增加 30 天死亡率。这些发现是产生假说的,应该在临床试验中进行检验。